Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now

Strong market trends and share price performance fortify CONMED's (CNMD) foothold in the niche markets.

    GNC Holdings to Boost International Business With New Deals

    GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.

      GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates

      Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.

        DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues

        Impressive results from Kidney Care business drove DaVita (DVA) in Q4.

          Myriad Genetics' Positive Study Data May Expand Customer Base

          Myriad Genetics (MYGN) leaves no stone unturned to drive the uptake of myRisk Hereditary Cancer test and strengthen the Molecular Diagnostics portfolio.

            5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now

            PerkinElmer (PKI) rides on synergies from the acquisition of EUROIMMUN and broadened product base.

              Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View

              Luminex's (LMNX) favorable tidings at the regulatory front in Q4 buoy optimism.

                Here's Why You Should Sweep Up Quest Diagnostics Right Now

                Quest Diagnostics' (DGX) latest acquisitions boost investors' confidence.

                  Becton, Dickinson Gains on Strong Q1 Results & Acquisitions

                  Acquisition of C.R.Bard and a solid FY18 guidance are key catalysts for Becton, Dickinson (BDX).

                    Amedisys (AMED) Strong on Home Health, Margin Decline a Woe

                    Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.

                      Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife

                      Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.

                        Abbott's FreeStyle LibreLink App Now Available in Europe

                        Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.

                          QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base

                          QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.

                            QIAGEN Strong on Molecular Diagnostics, Competition Rife

                            QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.

                              Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View

                              Bruker (BRKR) registers organic revenue growth on strength in NANO and BEST platforms in Q4.

                                Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down

                                Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.

                                  Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid

                                  Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.

                                    CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat

                                    A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.

                                      Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View

                                      Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.

                                        Illumina Banks on Strategic Partnerships, Competition Rife

                                        Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.

                                          Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag

                                          Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.

                                            STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up

                                            STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.

                                              Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar

                                              Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.

                                                Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up

                                                Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.

                                                  Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2

                                                  Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.